The modern trends in the diagnostic search for and the treatment of chronic rhinosinusitis with nasal polyps

Savlevich E.L.; Kozlov V.S.; Kurbacheva O.M.

doi:https://doi.org/10.17116/rosrino201826241

Close metadata

Recommended articles:

Influence of age and sex on values of SNOT-22 sinonasal test domains in children and adolescents with bronchial asthma. Russian Rhinology. 2025;(3):197-204

Sinonasal pathology in patients with primary ciliary dyskinesia. Russian Rhinology. 2025;(3):223-232

Efficacy of dupilumab application in bullous pemphigoid proceeding in presence of bronchial asthma. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):204-209

Study of serum cytokine concentration in primary patients with gastric cancer. P.A. Herzen Journal of Oncology. 2025;(2):25-29

Neutrophil elastase as a promising biomarker of low-grade inflammation in chronic non-communicable diseases. Russian Journal of Preventive Medicine. 2025;(4):142-148

Cytokine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12

Serum cytokines in patients with brain tumor undergoing uncomplicated and complicated postoperative period. Russian Journal of Anesthesiology and Reanimatology. 2025;(4):21-30

Monoclonal antibodies in the treatment of recurrent polyposis rhinosinusitis. Literature review. Russian Bulletin of Otorhinolaryngology. 2025;(4):96-104

Mechanisms of additivity of physiotherapeutic factors in complex therapy of polypous rhinosinusitis complicated by comorbidities. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2025;(3):5-11

Search for informative predictors of the development and progression of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):124-130

Abstract:

The problem of understanding the causes for the development of chronic rhinosinusitis with nasal polyps (CRSwNP) remains to be elucidated. Heterogeneity of CRSwNP development can be explained by different molecular and cellular pathways which lead to inflammation of the mucous membrane followed by its further remodelling. The recurrence of the polypous process is observed in 60—70% of the cases within 18 months after functional endoscopic surgical intervention on the nasal sinuses (FESS). The ongoing investigations have the objective to elaborate the fundamentally new methods for targeted therapy aimed at a specific biological substrate. The main difficulty encountered in the correct selection of the proper medications is to determine the most significant key biomarker at the molecular level in a particular patient, such the blockade of which would lead to regression of the pathological process. At present, monoclonal antibodies to IL-5, 13, IgE, alpha-chain of the IL-4 receptor, transmembrane receptor Siglec-8, transcription factor GATA-3 specific DNA enzyme are being developed and introduced in the clinical practice.

Keywords:

chronic rhinosinusitis with nasal polyps

endotypes

monoclonal antibodies

interleukins

bronchial asthma

Authors:

Savlevich E.L.

Training Scientific Medical Center of the Russian Federation Presidential Administration, Moscow, Russia, 121359

Kozlov V.S.

Kafedra otorinolaringologii FGBU UNMTs UD Prezidenta RF

Kurbacheva O.M.

Institute of Immunology, Federal Medico-Biological Agency, Moscow, Russia, 115478

Close metadata

References:

Lal D, Scianna JM, Stankiewicz JA. Efficacy of targeted medical therapy in chronic rhinosinusitis, and predictors of failure. American Journal of RhinoÂlogy & Allergy. 2009;23(4):396-400. https://doi.org/10.2500/ajra.2009.23.3334
Vlaminck S, Vauterin T, Hellings PW, Jorissen M, Acke F, Van Cauwenberge P, Bachert C, Gevaert P. The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: a 3-year prospective observational study. American Journal of Rhinology & Allergy. 2014;28(3):260-264. https://doi.org/10.1186/2045-7022-3-s2-o12
Kirdeeva AI, Kosyakov SYa. The peculiarities of endotyping and phenotyping of chronic rhinosinusitis. Russian rhinology. 2017;25(2):58-63. (In Russ.) https://doi.org/10.17116/rosrino201725258-63
Dennis SK, Lam K, Luong A. A review of classification schemes for chroÂnic rhinosinusitis with nasal polyposis endotypes. Laryngoscope Investig Otolaryngol. 2016;1(5):130-134. https://doi.org/10.1002/lio2.32
Savlevich EL, Simbirtsev AS, Bondareva GP, Kurbacheva OM. Role of cytokines in the development of chronic rhinosinusitis with polyps. Cytokines and inflammation. 2016;15(3-4):265-268. (In Russ.)
Pavlova KS, Kurbacheva OM, Galitskaya MA, Smirnov DS. Actual conception of allergen-specific immunotherapy mechanisms, potential biomarkers of efficacy and ways of enhancement. Russian Journal of Allergy. 2017;4-5(14):5-17. (In Russ.)
Khaidukov SV. Minor subsets of t-helper cells (Th thymic naive, Th central naive, Th9, Th22 and CD4+CD8+ double positive t-cells). Medical Immunology. 2014;15(6):503-512. (In Russ.) https://doi.org/10.15789/1563-0625-2013-6-503-512
Kim DW, Cho SH. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy, Asthma & Immunology Research. 2017;9(4):299-306. https://doi.org/10.4168/aair.2017.9.4.299
Pant H, Hughes A, Schembri M, Miljkovic D, Krumbiegel D. CD4+ and CD8+ regulatory T cells in chronic rhinosinusitis mucosa. American Journal of Rhinology & Allergy. 2014;28(2):83-89. https://doi.org/10.2500/ajra.2013.28.4014
Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, Bachert C. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61(11):1280-1289. https://doi.org/10.1111/j.1398-9995.2006.01225.x
Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, Wang H, ZhangÂ L, Bachert C. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. Journal of Allergy and Clinical Immunology. 2016;138(5):1344-1353. https://doi.org/10.1016/j.jaci.2016.05.041
Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald PJ. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;50(23):1-298. https://doi.org/10.4193/Rhino50E2
Kozlov VS, Savlevich EL. Chronic rhinosinusitis with nasal polyps. The recent trend in the studies of the pathogenesis, diagnosis and treatment of this disease. Vestnik otorinolaringologii. 2015;80(4):95-99. (In Russ.) https://doi.org/10.17116/otorino201580495-99
DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. The Laryngoscope. 2016;127(3):550-555. https://doi.org/10.1002/lary.26391
Ivanov AA, Beletskii IP. Therapy with monoclonal antibodies is a panacea or palliative? Remedium. 2011;3:12-16. (In Russ.)
Lam K, Kern RC, Luong A. Is there a Future for Biologics in the Management of Chronic Rhinosinusitis? International Forum of Allergy & Rhinology. 2016;6(9):935-942. https://doi.org/10.1002/alr.21780
Ba L, Zhang N, Meng J, Zhang J, Lin P, Zhou P, Liu S, Bachert C. The association between bacterial colonization and inflammatory pattern in Chinese chronic rhinosinusitis patients with nasal polyps. Allergy. 2011;66(10):1296-1303. https://doi.org/10.1111/j.1398-9995.2011.02637.x
Tokunaga T, Sakashita M, Haruna T, Asaka D, Takeno S, Ikeda H, Nakayama T, Seki N, Ito S, Murata J, Sakuma Y, Yoshida N, Terada T, Morikura I, Sakaida H, Kondo K, Teraguchi K, Okano M, Otori N, YoshikawaÂ M, Hirakawa K, Haruna S, Himi T, Ikeda K8, Ishitoya J, Iino Y, Kawata R, Kawauchi H, Kobayashi M, Yamasoba T, Miwa T, Urashima M, Tamari M18, Noguchi E, Ninomiya T, Imoto Y, Morikawa T, Tomita K, Takabayashi T, Fujieda S. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy. 2015;70(8):995-1003. https://doi.org/10.1111/all.12644
Zhang N, Van Crombruggen K, Gevaert E, Bachert C. Barrier function of the nasal mucosa in health and type-2 biased airway diseases. Allergy. 2016;71(3):295-307. https://doi.org/10.1111/all.12809
Blanchard C, Mingler MK, McBride M, Putnam PE, Collins MH, Chang G, Stringer K, Abonia JP, Molkentin JD, Rothenberg ME. Periostin facilitates eosinophil tissue infiltrati on in allergic lung and esophageal responses. Mucosal Immunology. 2008;1(4):289-296. https://doi.org/10.1038/mi.2008.15
Asano T, Kanemitsu Y, Takemura M, Yokota M, Fukumitsu K, Takeda N, Ichikawa H, Uemura T, Takakuwa O, Ohkubo H, Maeno K, Ito Y, Oguri T, Maki Y, Ono J, Ohta S, Nakamura Y, Izuhara K, Suzuki M, Niimi A. Serum periostin as a biomarker for comorbid chronic rhinosinusitis in patients with asthma. Annals of the American Thoracic Society. 2017;14(5):667-675. https://doi.org/10.1513/annalsats.201609-720oc
Miłoński J, Zielińska-Bliźniewska H, Przybyłowska K, Pietkiewicz P, Korzycka-Zaborowska B, Majsterek I, Olszewski J. Significance of cyclooxygenase-2 (COX-2), periostin (POSTN) and interleukin-4 (IL-4) gene expression in the pathogenesis of chronic rhinosinusitis with nasal polyps. European Archives of Oto-Rhino-Laryngology. 2015;272(12):3715-3720. https://doi.org/10.1007/s00405-014-3481-9
Ueki S, Konno Y, Takeda M, Moritoki Y, Hirokawa M, Matsuwaki Y, Honda K, Ohta N, Yamamoto S, Takagi Y, Wada A, Weller PF. Eosinophil extracellular trap cell death-derived DNA traps: Their presence in secretions and functional attributes. Journal of Allergy and Clinical Immunology. 2016;137(1):258-267. https://doi.org/10.1016/j.jaci.2015.04.041
Morshed M, Yousefi S, StÃ¶ckle C, Simon HU, Simon D. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy. 2012;67(9):1127-1137. https://doi.org/10.1111/j.1398-9995.2012.02868.x
Gevaert E, Zhang N, Krysko O, Lan F, Holtappels G, De Ruyck N, Nauwynck H, Yousefi S, Simon HU, Bachert C. Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation. Journal of Allergy and Clinical Immunology. 2017;139(6):1849-1860. https://doi.org/10.1016/j.jaci.2017.01.019
Wen W, Liu W, Zhang L, Bai J, Fan Y, Xia W, Luo Q, Zheng J, Wang H, Li Â Z, Xia J, Jiang H, Liu Z, Shi J, Li H, Xu G. Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy. Journal of Allergy and Clinical Immunology. 2012;129(6):1522-1528. https://doi.org/10.1016/j.jaci.2012.01.079
Schleimer RP, Schnaar RL, Bochner BS. Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression. Current Opinion in Allergy and Clinical Immunology. 2016;16(1):24-30. https://doi.org/10.1097/aci.0000000000000234
Yokoi H, Choi OH, Hubbard W, Lee HS, Canning BJ, Lee HH, Ryu SD, von Gunten S, Bickel CA, Hudson SA, Macglashan DW Jr, Bochner BS. Inhibition of FcÎµRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. Journal of Allergy and Clinical Immunology. 2008;121(2):499-505. https://doi.org/10.1016/j.jaci.2007.10.004
Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, De Ruyck N, Blomme K, Sousa AR, Marshall RP, Bachert C. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. Journal of Allergy and Clinical Immunology. 2011;128(5):989-995. https://doi.org/10.1016/j.jaci.2011.07.056
Van Crombruggen K, Zhang N, Gevaert P, Tomassen P, Bachert C. Pathogenesis of chronic rhinosinusitis: inflammation. Journal of Allergy and CliÂnical Immunology. 2011;128(4):728-732. https://doi.org/10.1016/j.jaci.2011.07.049
Kim CK. Eosinophil-derived neurotoxin: a novel biomarker for diagnosis and monitoring of asthma. Korean Journal of Pediatrics. 2013;56(1):8-12. https://doi.org/10.3345/kjp.2013.56.1.8
Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, Förster-Ruhrmann U, Kowalski ML, Olszewska-Ziąber A, Holtappels G, De Ruyck N, Wang X, Van Drunen C, Mullol J, Hellings P, Hox V, Toskala E, Scadding G, Lund V, Zhang L, Fokkens W, Bachert C. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. Journal of Allergy and Clinical Immunology. 2016;137(5):1449-1456. https://doi.org/10.1016/j.jaci.2015.12.1324
Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA. Effects of benralizumab on airway eosinophils in asthma with sputum eosinophilia. Journal of Allergy and Clinical Immunology. 2013;132(5):1086-1096. https://doi.org/10.1016/j.jaci.2013.05.020
Ketlinskii SA, Simbirtsev AS. Cytokines and inflammation. SPb.: Foliant; 2008. (In Russ.)
Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, Pirozzi G, Graham NM, Swanson B, Hamilton JD, Radin A, Gandhi NA, Stahl N, Yancopoulos GD, Sutherland ER. Effect of subcutaneous Dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469-479. https://doi.org/10.1001/jama.2015.19330
Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, ArronÂ JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG. Lebrikizumab treatment in adults with asthma. New England Journal of Medicine. 2011;365(12):1088-1098. https://doi.org/10.1056/nejmoa1106469
Brightling CE, Chanez P, Leigh R, Oâ€™Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E. Efficacy and safety of Tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet Respiratory Medicine. 2015;3(9):692-701. https://doi.org/10.1016/s2213-2600(15)00197-6
Nixon J, Newbold P, Mustelin T, Anderson GP, Kolbeck R. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacology & Therapeutics. 2017;169:57-77. https://doi.org/10.1016/j.pharmthera.2016.10.016
Ebenezer JA, Christensen JM, Oliver BG, Oliver RA, Tjin G, Ho J, Habib Â AR, Rimmer J, Sacks R, Harvey RJ. Periostin as a marker of mucosal remodelling in chronic rhinosinusitis. Rhinology. 2017;55(3):234-241. https://doi.org/10.4193/rhin16.215
Sheahan P, Ahn CN, Harvey RJ, Wise SK, Mulligan RM, Lathers DM, Schlosser RJ. Local IgE production in nonatopic nasal polyposis. J Otolaryngol Head Neck Surg. 2010;39(1):45-51.
Kato A, Peters A, Suh L, Carter R, Harris KE, Chandra R, Conley D, Grammer LC, Kern R, Schleimer RP. Evidence of a role for B cell-activating factor of the TNF family in the pathogenesis of chronic rhinosinusitis with nasal polyps. Journal of Allergy and Clinical Immunology. 2008;121(6):1385-1392. https://doi.org/10.1016/j.jaci.2008.03.002
Tan BK, Li QZ, Suh L, Kato A, Conley DB, Chandra RK, Zhou J, NortonÂ J, Carter R, Hinchcliff M, Harris K, Peters A, Grammer LC, Kern RC, Mohan C, Schleimer RP. Evidence for intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis with nasal polyps. Journal of Allergy and Clinical Immunology. 2011;128(6):1198-1206. https://doi.org/10.1016/j.jaci.2011.08.037
Bachert C, Zhang N, Van Zele T, Gevaert P, Patou J, Van Cauwenberge P. Staphylococcus aureus enterotoxins as immune stimulants in chronic rhinosinusitis. Clin Allergy Immunol. 2007;20:163-175.
Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-811. https://doi.org/10.1164/rccm.201208-1414oc
Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48(3):318-324. https://doi.org/10.4193/rhin09.144
Kim DW, Kulka M, Jo A, Eun KM, Arizmendi N, Tancowny BP, HongÂ SN, Lee JP, Jin HR, Lockey RF, Kim DK, Cho SH. Cross-talk between human mast cells and epithelial cells by IgE-mediated periostin production in eosinophilic nasal polyps. Journal of Allergy and Clinical Immunology. 2017;139(5):1692-1695. https://doi.org/10.1016/j.jaci.2016.09.026
Gauvreau GM, Arm JP, Boulet LP, Leigh R, Cockcroft DW, Davis BE, Mayers I, FitzGerald JM, Dahlen B, Killian KJ, Laviolette M, Carlsten C, Lazarinis N, Watson RM, Milot J, Swystun V, Bowen M, Hui L, Lantz AS, Meiser K, Maahs S, Lowe PJ, Skerjanec A, Drollmann A, Oâ€™Byrne PM. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. Journal of Allergy and Clinical Immunology. 2016;138(4):1051-1059. https://doi.org/10.1016/j.jaci.2016.02.027
Sel S, Wegmann M, Dicke T, Sel S, Henke W, Yildirim AO, Renz H, GarnÂ H. Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. Journal of Allergy and Clinical Immunology. 2008;121(4):910-916. https://doi.org/10.1016/j.jaci.2007.12.1175
Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H. Allergen-induced asthmatic responses modified by a GATA-3-specific DNAzyme. New England Journal of Medicine. 2015;372(21):1987-1995. https://doi.org/10.1056/nejmoa1411776